Psychotic Illness Can Be Predicted In Up To 80 Percent Of High-Risk Youth

Youth who are going to develop psychosis can be identified before their illness becomes full-blown 35 percent of the time if they meet widely accepted criteria for risk, but that figure rises to 65 to 80 percent if they have certain combinations of risk factors, the largest study of its kind has shown. Knowing what […]

INVEGA™ Shows Favorable Long Term Safety Profile In A One Year Study Of Patients With Schizophrenia

INVEGA™ (paliperidone) Extended-Release Tablets showed favorable long-term safety and tolerability during a one-year open-label extension (OLE) study, according to a new, company-sponsored study. In addition, patient symptom scores improved or were stable, on average, over this 52-week study1. The study was designed to evaluate the long-term safety of INVEGA™, an oral, atypical anti-psychotic approved for […]

Intra Cellular Therapies Presents Preclinical Data From Schizophrenia And Sleep Maintenance Programs

Intra-Cellular Therapies, Inc. (ITI) presented preclinical data on ITI-007, its first in class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) at a major medical meeting last week. The Company is developing ITI-007 for the treatment of schizophrenia and other related psychiatric conditions. In this presentation, ITI-007 was shown to possess a unique pharmacologic profile, […]

Iloperidone Phase III Clinical Data Demonstrate Efficacy And Favorable Safety And Tolerability Profile

Titan Pharmaceuticals, Inc. (AMEX: TTP) announced that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. These results were included as part of the recently filed New […]

New Drug Can Restore Social Ability In Schizophrenics

The social behaviour of rats displaying schizophrenic tendencies is restored when they are treated with two new potential drugs that seem to have unique effects on dopaminergic signalling. This is a conclusion of a thesis from the Sahlgrenska Academy at Goteborg University in Sweden. Schizophrenia is a severe psychiatric disorder with symptoms that include hallucinations […]

Titan Reports FDA Acceptance Of Iloperidone NDA

Titan Pharmaceuticals, Inc. (AMEX: TTP) announced that the U.S. Food and Drug Administration (FDA) officially accepted a New Drug Application (NDA) submitted for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. The NDA was submitted by Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). The NDA includes data from 35 clinical trials and more than 3,000 […]

Vanda Pharmaceuticals Receives FDA Acceptance Of Iloperidone New Drug Application

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia. Acceptance of the NDA confirms that the application is sufficiently complete for FDA review. About Schizophrenia Schizophrenia is a chronic, severe and […]

Potential Strategies For Treatment Of Neurodevelopmental And Psychiatric Diseases

Researchers have identified a master regulatory molecule that is responsible for triggering the remodeling of neuronal connections critical for learning. Malfunctioning of the connection-remodeling machinery that they identified may also play a role in mental retardation, schizophrenia, and drug addiction. Thus, said the researchers, knowledge of the machinery could lead to insights into those disorders. […]

Once-Daily SEROQUEL XL(R) Prevents Relapse In Patients With Schizophrenia Clear Long-term Benefit Leads To Early Completion Of Study

A new study, published in the November 2007 issue of Psychiatry 20071 found that the once daily formulation of SEROQUEL XL® in adult patients with schizophrenia significantly reduces the risk of psychotic relapse. The study was scheduled to last one year or until relapse, but significant differences in the relapse rate between active treatment and […]

|